

144. A method according to Claim 143 wherein said taxane is administered at a dosage of from about 20.0 mg/m² body surface area to about 75.0 mg/m² body surface area.

145. A method according to Claim 129 wherein said anthracycline anti-cancer agent is administered at a dosage of from about 3 mg/m² body surface area to about 130 mg/m² body surface area.

146. A method according to Claim 128 wherein the particle size of said aerosol is from about 0.1 µm to about 10.0 µm.

147. A method according to Claim 146 wherein the particle size of said aerosol is from about 1.0 µm to about 5.0 µm.

148. A method according to Claim 147 wherein the particle size of said aerosol is from about 2.0 µm to about 2.5 µm.

149. A method according to Claim 128 wherein one or more non-vesicant anti-cancer agents are administered by inhalation at the same time as the vesicant anticancer agent.

150. A method according to Claim 135 wherein said means for aerosolization is selected from the group consisting of metered dose inhalers, nebulizers, and dry powder inhalers.

REMARKS

This application is a continuation of US Serial No. 09/000,775 filed December 30, 1997.

Pursuant to Section 714.09 of the *Manual of Patent Examining Procedure* (MPEP), Applicants herewith submit an amendment preliminary to an action by the Office.

By this amendment, all previously pending claims have been cancelled. New Claims 128 – 150 have been added. The new claims do not introduce new matter and the present invention is fully supported and disclosed by the specification and claims as originally filed.

THE UNIVERSITY OF CHICAGO

p. 17, Table 1

4